Atea Pharmaceuticals Inc — Balance Sheet (NASDAQ:AVIR) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Total assets 863.63 M772.89 M666.71 M594.97 M464.67 M Total liabilities 315.83 M62.81 M26.14 M39.78 M25.8 M Total equity 547.8 M710.08 M640.57 M555.19 M438.87 M Total liabilities & shareholders' equities 863.63 M772.89 M666.71 M594.97 M464.67 M Total debt ————— Net debt —————

新闻

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea公司丙型肝炎治疗方案的三期临床试验结果预计2026年中期公布

Atea’s HCV treatment regimen phase 3 results expected mid-2026

Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)

Atea completes enrollment in HCV treatment phase 3 trial

Atea Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2025-11-14

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Cisco, Flutter, Manulife and more set to report earnings Wednesday

Atea制药公司的丙型肝炎药物组合在模型研究中显示出有希望的结果

Atea’s hepatitis C drug combination shows promising results in modeling study

Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway